FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003138831> ?p ?o ?g. }

• W2003138831 endingPage "559" @default.
• W2003138831 startingPage "540" @default.
• W2003138831 abstract "As part of our effort to identify glycoproteins that contribute to colon cancer progression, we have previously described a family of structurally related glycoproteins expressing β1–6 branched asparagine(Asn)-linked oligosaccharides defined by monoclonal antibody (MAb 1H9), which are differentially expressed, processed, and glycosylated by human colon carcinoma cell lines (Laferté and Loh [1992]; Biochem J; 283:193–201). MAb 1H9 immunoprecipitates three glycoproteins having apparent sizes of 92–100, 66–70, and 25 kDa, the size heterogeneity attributable to cell-type specific glycosylation differences. We report on the basis of partial protein and cDNA sequence information, that the 100-kDa glycoprotein detected by MAb 1H9 is identical to the 90-kDa glycoprotein variably known as tumor-associated antigen 90K (TAA90K), Mac-2 binding protein, and cyclophilin C-associated protein. Using a PCR-based cloning strategy, the complete cDNA encoding TAA90K was cloned into the eukaryotic expression vector pCDNA-3 (pCD-TAA90Kwt) and the protein expressed in COS-1 cells. A [35S]methionine-labeled 60-kDa polypeptide, processed to an endoglycosidase H-sensitive 74-kDa glycoprotein in the presence of dog pancreas microsomes, was detected in a coupled transcription/translation in vitro reaction. The in vitro-translated 60-kDa polypeptide and N-glycanase-treated TAA90K (60-kDa species) immunoprecipitated from HT29 cells were shown to be structurally identical by limited proteolytic peptide mapping. Using a new panel of 11 TAA90K-specific monoclonal antibodies, including five specific for human TAA90K and six cross-reactive with a 90-kDa species expressed by COS-1 cells, we have detected conformational differences between recombinant wild-type TAA90K, in vitro-synthesized TAA90K, and mutant forms of TAA90K containing point mutations at residues 189, 223, and 259. Furthermore, we have shown that these mutant forms of TAA90K, as well as a truncated form of TAA90K containing amino acid residues 1–383, are defective in secretion. These studies demonstrate the potential usefulness of TAA90K-specific monoclonal antibodies for examining the structure and function of TAA90K, and highlight the contribution of specific amino acid residues to its normal processing and secretion. J. Cell. Biochem. 77:540–559, 2000. © 2000 Wiley-Liss, Inc." @default.
• W2003138831 created "2016-06-24" @default.
• W2003138831 creator A5083526380 @default.
• W2003138831 creator A5089488117 @default.
• W2003138831 creator A5047233621 @default.
• W2003138831 date "2000-06-15" @default.
• W2003138831 modified "2023-10-17" @default.
• W2003138831 title "Monoclonal antibodies specific for human tumor-associated antigen 90K/Mac-2 binding protein: Tools to examine protein conformation and function" @default.
• W2003138831 cites W1496787899 @default.
• W2003138831 cites W1525792717 @default.
• W2003138831 cites W1529251418 @default.
• W2003138831 cites W1534850320 @default.
• W2003138831 cites W1561117001 @default.
• W2003138831 cites W1566528463 @default.
• W2003138831 cites W1638424324 @default.
• W2003138831 cites W1917291162 @default.
• W2003138831 cites W1953545855 @default.
• W2003138831 cites W1970007744 @default.
• W2003138831 cites W1972766406 @default.
• W2003138831 cites W1978884666 @default.
• W2003138831 cites W1985751866 @default.
• W2003138831 cites W1986129246 @default.
• W2003138831 cites W2003193695 @default.
• W2003138831 cites W2005145242 @default.
• W2003138831 cites W2006850107 @default.
• W2003138831 cites W2009524774 @default.
• W2003138831 cites W2009740215 @default.
• W2003138831 cites W2015644906 @default.
• W2003138831 cites W2018254342 @default.
• W2003138831 cites W2024191618 @default.
• W2003138831 cites W2033201741 @default.
• W2003138831 cites W2034277598 @default.
• W2003138831 cites W2038484123 @default.
• W2003138831 cites W2039863802 @default.
• W2003138831 cites W2042863201 @default.
• W2003138831 cites W2043039723 @default.
• W2003138831 cites W2056799965 @default.
• W2003138831 cites W2058852380 @default.
• W2003138831 cites W2060132928 @default.
• W2003138831 cites W2061327866 @default.
• W2003138831 cites W2076183448 @default.
• W2003138831 cites W2077546649 @default.
• W2003138831 cites W2079268907 @default.
• W2003138831 cites W2084484190 @default.
• W2003138831 cites W2100837269 @default.
• W2003138831 cites W2118877270 @default.
• W2003138831 cites W2126719129 @default.
• W2003138831 cites W2164358316 @default.
• W2003138831 cites W4322696075 @default.
• W2003138831 doi "https://doi.org/10.1002/(sici)1097-4644(20000615)77:4<540::aid-jcb3>3.0.co;2-i" @default.
• W2003138831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10771511" @default.
• W2003138831 hasPublicationYear "2000" @default.
• W2003138831 type Work @default.
• W2003138831 sameAs 2003138831 @default.
• W2003138831 citedByCount "15" @default.
• W2003138831 countsByYear W20031388312013 @default.
• W2003138831 countsByYear W20031388312014 @default.
• W2003138831 countsByYear W20031388312017 @default.
• W2003138831 countsByYear W20031388312018 @default.
• W2003138831 countsByYear W20031388312019 @default.
• W2003138831 countsByYear W20031388312021 @default.
• W2003138831 countsByYear W20031388312022 @default.
• W2003138831 crossrefType "journal-article" @default.
• W2003138831 hasAuthorship W2003138831A5047233621 @default.
• W2003138831 hasAuthorship W2003138831A5083526380 @default.
• W2003138831 hasAuthorship W2003138831A5089488117 @default.
• W2003138831 hasConcept C104317684 @default.
• W2003138831 hasConcept C108625454 @default.
• W2003138831 hasConcept C119062480 @default.
• W2003138831 hasConcept C147483822 @default.
• W2003138831 hasConcept C1491633281 @default.
• W2003138831 hasConcept C153911025 @default.
• W2003138831 hasConcept C159654299 @default.
• W2003138831 hasConcept C187882448 @default.
• W2003138831 hasConcept C203014093 @default.
• W2003138831 hasConcept C2777313579 @default.
• W2003138831 hasConcept C2779571893 @default.
• W2003138831 hasConcept C2780654058 @default.
• W2003138831 hasConcept C542903549 @default.
• W2003138831 hasConcept C54355233 @default.
• W2003138831 hasConcept C55493867 @default.
• W2003138831 hasConcept C71829478 @default.
• W2003138831 hasConcept C86803240 @default.
• W2003138831 hasConceptScore W2003138831C104317684 @default.
• W2003138831 hasConceptScore W2003138831C108625454 @default.
• W2003138831 hasConceptScore W2003138831C119062480 @default.
• W2003138831 hasConceptScore W2003138831C147483822 @default.
• W2003138831 hasConceptScore W2003138831C1491633281 @default.
• W2003138831 hasConceptScore W2003138831C153911025 @default.
• W2003138831 hasConceptScore W2003138831C159654299 @default.
• W2003138831 hasConceptScore W2003138831C187882448 @default.
• W2003138831 hasConceptScore W2003138831C203014093 @default.
• W2003138831 hasConceptScore W2003138831C2777313579 @default.
• W2003138831 hasConceptScore W2003138831C2779571893 @default.
• W2003138831 hasConceptScore W2003138831C2780654058 @default.
• W2003138831 hasConceptScore W2003138831C542903549 @default.
• W2003138831 hasConceptScore W2003138831C54355233 @default.
• W2003138831 hasConceptScore W2003138831C55493867 @default.

• next